ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 20, 2018. The filing serves to announce the company's financial results for the quarter and full year ended December 31, 2017.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the main text. It directs readers to the attached press release (Exhibit 99.1) for the announcement of results for the quarter and year ended December 31, 2017.
Guidance, Outlook, and Risks
The provided text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The report states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 20, 2018) for specific revenue, net loss, and cash position figures.
- Verify the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.
- Confirm the exact date of the reported period (ended December 31, 2017) against the filing date (March 20, 2018).
- Note that the financial data in this 8-K is furnished and not incorporated by reference into other filings unless expressly stated.